Trials / Completed
CompletedNCT00384098
Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis
A Randomized, Double-blind, Parallel-group, 4-arm, 12-week Study to Evaluate the Safety and Efficacy of Topically Applied CTA018 vs Vehicle for the Treatment of Adult Subjects With Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 140 (planned)
- Sponsor
- OPKO Health, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Vitamin D and its analogs are currently widely used for the treatment of psoriasis. The study drug (CTA018) is a novel analog of vitamin D, and this Phase 2 study will investigate the efficacy and safety of CTA018 in the treatment of psoriasis. Patients with chronic plaque psoriasis will receive one of three doses of CTA018 cream or vehicle (no study drug) daily for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CTA018 cream |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2006-10-04
- Last updated
- 2014-09-29
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00384098. Inclusion in this directory is not an endorsement.